217 related articles for article (PubMed ID: 38241710)
21. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
22. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
23. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
25. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract][Full Text] [Related]
26. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
27. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L; Keyomarsi K
Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784
[TBL] [Abstract][Full Text] [Related]
29. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
30. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract][Full Text] [Related]
31. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
32. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
33. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
34. Complex interplay between FMRP and DHX9 during DNA replication stress.
Chakraborty A; Dutta A; Dettori LG; Daoud R; Li J; Gonzalez L; Xue X; Hehnly H; Sung P; Bah A; Feng W
J Biol Chem; 2024 Jan; 300(1):105572. PubMed ID: 38110032
[TBL] [Abstract][Full Text] [Related]
35.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract][Full Text] [Related]
36. TDRD3 promotes DHX9 chromatin recruitment and R-loop resolution.
Yuan W; Al-Hadid Q; Wang Z; Shen L; Cho H; Wu X; Yang Y
Nucleic Acids Res; 2021 Sep; 49(15):8573-8591. PubMed ID: 34329467
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract][Full Text] [Related]
38. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
39. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Sanij E; Hannan KM; Xuan J; Yan S; Ahern JE; Trigos AS; Brajanovski N; Son J; Chan KT; Kondrashova O; Lieschke E; Wakefield MJ; Frank D; Ellis S; Cullinane C; Kang J; Poortinga G; Nag P; Deans AJ; Khanna KK; Mileshkin L; McArthur GA; Soong J; Berns EMJJ; Hannan RD; Scott CL; Sheppard KE; Pearson RB
Nat Commun; 2020 May; 11(1):2641. PubMed ID: 32457376
[TBL] [Abstract][Full Text] [Related]
40. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]